Safety and Efficacy Study of Serostim® Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Safety and Efficacy Study of Serostim® Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome (NCT01077960), a non-randomized phase 3 study. The primary outcome is Change From Baseline to Week 12 in Trunk Fat as Assessed by Dual-Energy X-Ray Absorptiometry (DXA) Scan.

2. Clinical Question

In plain terms, the study concerned body composition after a further course of Serostim among selected participants from the earlier study. The clinical question was whether trunk fat changed over the 12-week follow-up period in the analysis population, rather than whether Serostim outperformed a concurrent placebo or another treatment. The record also lists secondary changes in waist circumference, insulin-like growth factor I, and measures from oral glucose tolerance testing. Those outcomes broaden the description of body composition and metabolic measurements, but they do not supply a control group or establish comparative effects. The posted record does not report the primary endpoint estimate, its variability, or numerical results for the listed secondary outcomes.

3. Trial Design

NCT01077960 is a Phase III, multi-center, open follow-up study of Serostim in people with human immunodeficiency virus-associated adipose redistribution syndrome. It was non-randomized, had no masking, and used a single-group model. The registry lists enrollment of 126 and marks the study completed. Its recorded start was 2005-02, and its primary completion was 2006-01.

The follow-up study was linked to Serono Study 24380. In that antecedent study, Group A received Serostim 4 mg daily during the first 12 weeks and was then re-randomized for the maintenance phase, Weeks 12-36, to Serostim 2 mg on alternate days or placebo on alternate days. For Study 25373, participants assigned to Group A who completed all visits without a major protocol violation were eligible to enroll for 12 weeks of re-treatment with Serostim 4 mg daily. Thus, the current study’s treatment course followed a prior 36-week treatment history; it was not a new randomized comparison.

The analysis population for the primary outcome is described as subjects who received at least one dose of study drug. The registry does not report how this population relates numerically to the enrollment count beyond the posted safety risk count of 126. It also does not report a control group, a random allocation procedure for this follow-up study, or a masking procedure; the design fields identify it as non-randomized and unmasked.

Safety monitoring included adverse-event recording and laboratory assessments, including fasting glucose, fasting insulin, routine biochemistry, and hematology. At Week 12 or study termination, body composition was reassessed with anthropometry and DXA. The record also describes IGF-I, IGFBP-3, fasting lipid profile, and oral glucose tolerance testing at termination. These descriptions indicate the range of planned assessments, but do not establish that every measurement was available for every participant. Details of the statistical analysis plan, including handling of missing measurements, are not reported in the registry record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: Any subject who was enrolled in Serono Study 24380, assigned to Group A, and fully completed all study visits without major protocol violations was to be allowed to enroll in Study 25373

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: The analysis population reported here comprised the subjects who received at least one dose of study drug

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Change From Baseline to Week 12 in Trunk Fat as Assessed by Dual-Energy X-Ray Absorptiometry (DXA) Scan, measured over baseline to 12 weeks.

The primary endpoint was change from baseline to Week 12 in trunk fat, assessed by dual-energy X-ray absorptiometry (DXA) and expressed in kilograms. It is described as a mean for the analysis population comprising subjects who received at least one dose of study drug. The endpoint therefore summarizes an average within-participant change over the treatment period, rather than a difference between two concurrent treatment groups.

Trunk fat is a body-composition measure relevant to the condition under study. DXA is the stated measurement method for this endpoint. In general, a continuous endpoint such as change in trunk fat can retain information about the size and direction of individual measurements, while a group mean gives a concise summary of average change. The mean alone does not show how varied participants’ changes were; the standard deviation is the registry’s specified dispersion measure, but its numerical value is not reported in the record.

The registry record does not report the mean change, standard deviation, confidence interval, or a test result for this primary endpoint. It is therefore not possible to describe the observed direction or size of the average change, or to characterize its statistical precision from the posted results. The endpoint definition identifies what was to be measured and when, but it is not itself evidence of an observed treatment effect.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The central statistical feature is the single-group structure. Each analyzed participant contributes a baseline measurement and a Week 12 measurement for the primary endpoint, and the endpoint is defined as mean change over that interval. This is a within-participant comparison across time. It is not the same estimand as a difference in mean change between a treatment group and a control group. The registry identifies the study as non-randomized and unmasked, so the follow-up does not provide random allocation or blinded assessment as safeguards against bias.

What does a mean change represent?

For a continuous measurement, an individual change is the value at follow-up considered relative to that participant’s baseline value. The mean change summarizes the average of those individual changes in the analysis population. The mean can be informative about the group’s central tendency, but it does not show the distribution of changes. Participants may vary around the mean, and a mean near no change could coexist with differing individual changes in opposite directions. The registry specifies standard deviation as the measure of dispersion, but does not report its numerical value for the primary endpoint.

General statistical explanation: the standard deviation describes how spread out individual measurements are around their mean. It is not the same as the standard error, which describes the sampling uncertainty of an estimate. A confidence interval is commonly used to express uncertainty around an estimated mean or contrast. The registry record does not report a confidence interval or standard error for the primary endpoint, so its precision cannot be evaluated from the posted outcome information.

Why does the lack of a comparator matter?

A treatment effect is ordinarily interpreted through a contrast between outcomes under different treatment conditions. In this study, the recorded design has one treatment group and no concurrent comparator. The baseline measurement provides a reference point, but participants at baseline are not a separate control group. Changes over time may be associated with treatment, but the design cannot distinguish treatment effects from time-related changes, other influences, or regression toward typical values after an unusually high or low measurement. This is a general limitation of before-and-after evidence, not a claim that any particular alternative explanation occurred in this study.

The earlier Study 24380 included treatment assignments and a later maintenance-phase re-randomization, but those features belong to the antecedent study. They do not turn Study 25373 into a randomized comparison. The follow-up population was eligible based on prior Group A assignment, completion of study visits, and absence of a major protocol violation. Such selection means the study’s population is not automatically interchangeable with all people who have the condition.

How should endpoint and analysis populations be read?

The primary endpoint description names trunk fat by DXA, the baseline-to-Week 12 timeframe, kilograms as the unit, and the mean as the summary. The stated analysis population comprises participants who received at least one dose of study drug. This definition is important because an endpoint estimate applies to the analyzed population, not necessarily every person enrolled or eligible. The registry does not report the number with observed primary endpoint data, the number excluded from that analysis, or how missing measurements were handled.

The record lists secondary outcomes covering waist circumference, IGF-I, fasting insulin, 120-minute glucose, and fasting glucose. It reports six outcome measures and six analyses. These entries identify measures under study; they do not provide numerical results or specify whether any particular analysis was adjusted for baseline values, covariates, or multiple testing. Those analytical details are not reported in the registry record.

What do the sample-size illustrations mean?

General statistical explanation: planning calculations estimate the number of participants needed under specified assumptions to detect an effect using a chosen design and testing threshold. They depend on the size of the effect to be detected, outcome variability, allocation, and analysis assumptions. A planning illustration based on an observed effect is not an independent confirmation of that effect. Nor does a planned sample size reveal the probability that a result is true or establish what the study actually observed.

The record describes an illustrative calculation using a two-sided significance level of 0.05, equal allocation between two arms, a normal approximation, and effects defined as fractions of the observed effect. For non-time-to-event outcomes, the stated convention is participants per arm; time-to-event calculations use a total event count. No numerical planning outputs are included in the registry record for this explanation. The trial itself is single-group, so an illustrative equal-allocation two-arm calculation should not be mistaken for the actual study design.

General statistical explanation: over-dispersion matters when outcome variability is greater than an analysis model assumes. If variability is underestimated, uncertainty can be understated and tests can appear more informative than warranted. The primary endpoint is continuous and the registry names standard deviation, but there is no reported numerical dispersion estimate to assess. No particular model, variance assumption, or correction for over-dispersion is stated for the endpoint.

Finally, a p-value, if reported, would address compatibility between data and a specified null model under statistical assumptions; it would not measure the size or clinical importance of a change. No primary endpoint p-value is reported in the registry record. With no reported estimate, dispersion, interval, or test result, the statistical evidence for the primary endpoint cannot be characterized beyond its definition and design context.

10. Confidence Intervals for Each Arm

No two-arm comparison is shown for this trial, but each arm's mean can be given with a t-based 95% confidence interval computed from the posted mean, spread and number of participants.

R code and output

arm <- c("Serostim")
n   <- c(106)
m   <- c(-1.7)
sp  <- c(1.4)
sd  <- sp      # posted standard deviations
for (i in seq_along(n)) {
  se <- sd[i] / sqrt(n[i]); h <- qt(0.975, n[i] - 1) * se
  cat(sprintf("CARM|%s|%d|%.3f|%.3f|%.3f|%.3f\n", arm[i], n[i], m[i], sd[i], m[i] - h, m[i] + h))
}

CARM  Serostim  106  -1.700  1.400  -1.970  -1.430

11. Multiplicity, Missing Data and Analysis Populations

The registry lists a primary outcome and several secondary outcomes. The primary outcome is mean change in trunk fat from baseline to Week 12. Secondary outcomes include changes in waist circumference and IGF-I, plus oral glucose tolerance testing measures for fasting insulin, 120-minute glucose, and fasting glucose. The record lists six outcome measures and six analyses. Considering multiple outcomes can increase the chance of apparently notable findings when many statistical tests are conducted. Whether the analysis plan controlled that issue, prioritized specific secondary outcomes, or adjusted significance thresholds is not reported in the registry record.

Multiplicity also concerns multiple analyses of the same outcome, such as alternative populations, models, or time points. The record does not describe whether such analyses were conducted or how they were handled. The outcome list alone is not enough to determine the number of inferential tests or the intended hierarchy among them. The numerical results and test statistics for the secondary measures are not reported in the registry record, so no outcome-by-outcome assessment is possible.

The analysis population is defined as participants who received at least one dose of study drug. That definition does not tell readers how many had an observed Week 12 DXA measurement or whether all enrolled participants were included in each outcome analysis. The number with missing endpoint data, reasons for missingness, any imputation approach, and sensitivity analyses for missing data are not reported in the registry record. The handling of early termination assessments is also not specified beyond the description that reassessment occurred at Week 12 or at study termination.

These omissions matter because an analysis based on participants with available measurements may differ from one that accounts for all enrolled participants. Missingness can affect both the amount of information and the interpretation of the estimate. Without counts, methods, or sensitivity analyses, the impact of missing measurements cannot be evaluated. The record also does not report whether the analysis population was prespecified in a statistical analysis plan.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: cardiac failure congestive (0.8%), diverticulitis (0.8%).

The safety figures list 126 participants at risk for serious adverse events and 126 at risk for other adverse events in the Serostim group. The posted counts are 2 for serious adverse events and 89 for other adverse events. The registry also lists congestive cardiac failure and diverticulitis among the top serious adverse event terms, each at 0.8%. These are descriptive safety figures; the record does not provide a concurrent control group for comparison.

General statistical explanation: a count of participants with an event is not the same as a count of all event episodes, since one participant may experience more than one event. The registry summary does not clarify in the registry record whether the posted counts represent participants or event episodes, so they should be read as the registry’s reported counts rather than interpreted beyond that. A serious adverse event category is distinct from an assessment of whether an event was caused by treatment.

The record does not report a treatment-relatedness assessment alongside these figures. Deaths are not reported in the registry record. The top serious-event terms each have the same listed percentage, but the underlying event details, timing, outcomes, and participant-level overlap are not described. Without a comparator and fuller event-level information, these counts cannot establish comparative safety or causation.

13. What the Result Does, and Does Not, Mean

The study documents a 12-week course of Serostim re-treatment in a selected follow-up population with human immunodeficiency virus-associated adipose redistribution syndrome. Its primary question concerns mean change in trunk fat measured by DXA from baseline to Week 12. The registry record identifies the endpoint and analysis population, but does not report the numerical mean change or standard deviation. The direction, magnitude, and precision of the primary result therefore cannot be described from the posted results.

Even if a within-group change were available, a single-group before-and-after study would not by itself establish that treatment caused the change. There is no concurrent control group, and the follow-up is non-randomized and unmasked. Baseline is a measurement time, not a randomized comparator. The design can describe a course over time in the analyzed participants, but cannot separate treatment-associated change from other influences with the strength of a controlled comparison.

The study population also has a specific history. Participants were eligible through prior assignment to Group A in Study 24380, completion of all study visits, and absence of a major protocol violation. They had undergone an earlier treatment course and maintenance phase before re-treatment. The findings therefore would not automatically generalize to people with the condition who did not participate in the earlier study or who did not meet the follow-up eligibility conditions.

The safety summary includes reported adverse-event counts and two top serious-event terms, but these figures do not establish whether events were caused by Serostim. The record does not include a comparative safety group, and deaths are not reported in the registry record. The listed secondary outcomes indicate additional measurements, but numerical secondary results are not available in the registry record.

The responsible interpretation is limited to the study’s design, population description, endpoints, and reported safety summary. The registry record does not report the primary numerical outcome needed to assess average trunk-fat change or its statistical precision. The study should not be read as a controlled estimate of treatment effect or as proof of benefit or lack of benefit.

14. Why This Trial Matters Statistically

This trial matters statistically because it illustrates the distinction between measuring change and estimating a comparative treatment effect. The primary endpoint is defined as mean change from baseline to Week 12 in trunk fat. That is a meaningful descriptive target, but a single-group estimate does not answer what would have happened to similar participants over the same period under a different treatment or no re-treatment.

The design also highlights how a follow-up cohort can be shaped by earlier study participation. Eligibility depended on prior Group A assignment, completion of all visits, and no major protocol violation. Those conditions may define a clinically and statistically particular population. Any inference should remain tied to that population and its prior treatment history, rather than being generalized automatically to all people with the condition.

A further statistical lesson is that an endpoint definition is not a result. The registry identifies the measure, timing, unit, summary statistic, and dispersion type, yet does not report the primary mean change or standard deviation. Without those estimates, readers cannot assess the observed size, spread, or precision. A complete statistical interpretation requires outcome values as well as a study design that supports the intended inference.

The listed sample-size assumptions also show why planning and evidence must remain distinct. A planning illustration using an observed effect and hypothetical two-arm allocation does not convert this actual single-group follow-up into a controlled trial. Such calculations are design aids, not observed power and not proof that an effect occurred. Reading these features together encourages attention to the estimand, population, comparator, and uncertainty rather than relying on a trial label or endpoint title alone.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The main limitation for interpreting efficacy is the non-randomized, single-group design without a concurrent control. A baseline assessment can anchor a description of subsequent change, but cannot provide the counterfactual comparison needed to isolate treatment effects. The study was also unmasked, as recorded in the registry.

The follow-up population was selected from an earlier study: only participants assigned to Group A who completed all visits without a major protocol violation were eligible. This selection and the earlier 36-week treatment history limit how broadly the findings could be applied, even if complete outcome results were available. The registry does not report how many eligible participants declined or were not enrolled.

The primary numerical outcome is not reported in the registry record. The missing mean change, standard deviation, and confidence interval prevent assessment of the endpoint’s magnitude and precision. Numerical results for secondary outcomes are not included in the registry record. The record also does not report the number with observed primary endpoint data, missing-data handling, or sensitivity analyses.

Further analytical details are not reported, including a statistical analysis plan, methods for multiplicity, and any adjustment or model used for the continuous endpoint. Safety results are descriptive and have no concurrent control for comparison; event-level details and treatment-relatedness are not given in the record details. Deaths are not reported in the registry record. These limitations mean that neither comparative efficacy nor comparative safety can be established from the information described.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: Safety and Efficacy Study of Serostim® Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome — NCT01077960.
• Registry record last updated 2013-08-07; status last verified 2013-08.
• Results first posted 2010-06-23.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

NCT01077960 is a completed Phase III, multi-center, open, non-randomized, single-group follow-up study sponsored by EMD Serono. The registry lists enrollment of 126, a start date of 2005-02, and primary completion in 2006-01. Participants received Serostim 4 mg daily for 12 weeks after prior treatment in Serono Study 24380.

The primary endpoint was mean change in trunk fat by DXA from baseline to Week 12, among subjects who received at least one dose. The numerical primary result and its standard deviation are not reported in the registry record. Listed secondary outcomes include waist circumference, IGF-I, and oral glucose tolerance testing measures. The safety summary reports 2 serious and 89 other adverse events among 126 at risk in the Serostim group; deaths are not reported in the registry record.